MENINGOCOCCAL VACCINE

MENINGOCOCCAL VACCINE

Meningococcal vaccine A+C, which contain 50 meg each of purified lympholized polysaccharide of Neisseria meningitides group A and C. Effectiveness of the vaccine is purely group specific.

Indications

1. All residents of an epidemic area
2. Close population groups, say schools
3. All contacts of an index case, especially family members(in addition to the drug prophylaxis).
4. High-risk groups: Asplenemia and immune (complement) deficiency.

Dose

Under 2 years: 0.5 ml (deep SC), preferably in deep infraspinal fossa, in a single dose. 2-4 years: 2 injections at 1 year gap Over 4 years: 2 injections at 5-year gap.

Side-effects

Local redness and edema, pyrexia